Month: September 2023

Datopotamab deruxtecan demonstrated statistically significant and clinically meaningful progression-free survival benefit in patients with HR-positive, HER2-low or negative breast cancer in TROPION-Breast01 Phase III trial

09/29/2023

First Phase III results in breast cancer for AstraZeneca and Daiichi Sankyo’s datopotamab deruxtecan Plans for global regulatory submissions underway Excerpt from the Press Release: WILMINGTON, Del.–(BUSINESS WIRE)–Positive high-level results from the TROPION-Breast01 Phase III trial showed datopotamab deruxtecan (Dato-DXd) demonstrated a statistically significant and clinically meaningful improvement for the primary endpoint of progression-free survival…

Read More

Via Nova Therapeutics Announces FDA clearance of Investigational New Drug (IND) application for VNT-101, a novel direct-acting antiviral against Influenza A virus

09/28/2023

Excerpt from the Press Release: OAKLAND, Calif., Sept. 21, 2023 /PRNewswire/ — Via Nova Therapeutics, Inc., a biotechnology company focused on discovering and developing therapeutics to treat viral infections with significant unmet medical need, today announced the clearance of its Investigational New Drug (IND) application from the U.S. Food and Drug Administration (FDA) for its…

Read More

UCSF QBI, University College London, and Mount Sinai Identify Shared Molecular Mechanisms Across SARS-CoV-2 Variants that Allow Virus to Thrive Despite Vaccination

09/27/2023

–  Findings show viral proteins outside of Spike across Alpha, Beta, Gamma, Delta and Omicron SARS-CoV-2 variants are responsible for innate immune suppression and escape from human immune system barriers – Elucidation of common evolutionary thread provides key biologic target against future COVID-19 variants and other pandemics Excerpt from the Press Release: SAN FRANCISCO and…

Read More

Ocugen Announces Positive Clinical Study Update from the Phase 1/2 Trial of OCU400, a Modifier Gene Therapy Product Candidate, for the Treatment of Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA)

09/26/2023

Excerpt from the Press Release: MALVERN, Pa., Sept. 13, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, biologics, and vaccines, today announced a clinical study update for Retinitis Pigmentosa (RP) participants treated in the Phase 1/2 trial…

Read More

Vincerx Pharma Doses First Patient in the Phase 1 Clinical Trial Evaluating VIP943

09/25/2023

Phase 1 trial enrolling patients with relapsed/refractory AML, MDS and B-cell ALL Excerpt from the Press Release: PALO ALTO, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) — Vincerx Pharma, Inc. (Nasdaq: VINC)(“Vincerx”), a biopharmaceutical company aspiring to address the unmet medical needs of patients with cancer through paradigm-shifting therapeutics, today reported that the first patient has been…

Read More

Meet with Christopher Kata and the TrialStat team at the “Octane Medical Innovations Forum (MIF)” October 25th to 26th!

09/25/2023

Christopher Kata and the TrialStat team are attend this years “Octane Medical Innovations Forum” meeting on October 25th through the 26th in Irvine, California. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting! We’re looking forward to meeting with you and providing live, personalized demonstrations of our…

Read More

Charles River and Related Sciences Enter Multi-Program Collaboration to Pursue AI-Enabled Drug Discovery Utilizing Logica

09/22/2023

Logica, an offering from Charles River and Valo Health, will be used to discover first-in-class therapeutics against high value targets in the Related Sciences portfolio Excerpt from the Press Release: WILMINGTON, Mass. & DENVER–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL) and Related Sciences (“RS”), a data science-driven drug discovery firm, today announced a multi-program…

Read More

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

09/21/2023

Excerpt from the Press Release: Zygel™ (ZYN002) achieved statistically significant and clinically meaningful improvements from baseline in multiple efficacy assessments and was generally well-tolerated through 38 weeks of treatment in INSPIRE, a Phase 2 trial with Zygel in children and adolescents with 22q11.2 deletion syndrome (22q) Devon, PA, September 14, 2023 – Zynerba Pharmaceuticals, Inc.…

Read More

NeuroBo Pharmaceuticals Doses First Patient in Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of NASH

09/20/2023

Two-Part Design Provides Optionality for Interim Analysis in First Half of 2024 Full Data Readout Expected in the Second Half of 2024 Excerpt from the Press Release: BOSTON, Sept. 15, 2023 /PRNewswire/ — NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company on a quest to transform cardiometabolic diseases, today announced dosing of the first…

Read More

Student researcher collaborating with Indigenous community to improve cancer screening

09/19/2023

OICR is hosting Jayson Pomfret as part of a unique summer internship program. Excerpt from the Press Release: Jayson Pomfret understands that meaningful cancer research happens in the community as well as at the lab bench. Pomfret is an undergraduate student in Queen’s University’s Bachelor of Health Sciences program who wants to pursue a career…

Read More